SFXN4: A Drug Target / Disease Biomarker (G119559)

Target Name: SFXN4

NCBI ID: G119559

SFXN4

SFXN4: A Drug Target / Disease Biomarker

SFXN4, short for Sphingomyelin A sulfate neurotrophic factor, is a protein that is expressed in the central nervous system (CNS) and is involved in the development and maintenance of the myelin sheath that surrounds the neurons. It has been identified as a potential drug target for various neurological disorders, including multiple sclerosis and chronic pain.

Myelin is the protective sheath that surrounds the neurons in the CNS, and it is responsible for allowing the neurons to communicate with each other and for protecting them from physical and chemical injuries. Myelin is made up of several different proteins, including SFXN4, which is known to be involved in the production and maintenance of the myelin sheath.

SFXN4 is a transmembrane protein that is expressed in the CNS, including the diencephalon, brainstem, and spinal cord. It is characterized by a unique structure that consists of an extracellular domain, a transmembrane region, and an intracellular tail. The extracellular domain of SFXN4 contains a protein that is involved in the interaction with cell surface receptors, while the transmembrane region contains a protein that is involved in the interaction with the extracellular matrix. The intracellular tail of SFXN4 contains a protein that is involved in the interaction with other proteins within the CNS.

SFXN4 is involved in the development and maintenance of the myelin sheath, and it is thought to play a key role in the regulation of neuronal communication and the maintenance of the normal structure of the myelin sheath. It is involved in the production of the myelin sheath, and it is also involved in the removal of damaged myelin sheath.

SFXN4 has been identified as a potential drug target for multiple sclerosis, a chronic and debilitating neurological disorder that is characterized by the destruction of the myelin sheath. Multiple sclerosis is a demyelinating disease that can cause weakness, muscle weakness, and vision problems. It is estimated that there are over 400,000 people in the United States with multiple sclerosis, and the number of people with the disease is expected to reach over 60 million by the year 2026.

SFXN4 has also been identified as a potential drug target for chronic pain, including neuropathic pain. Neuropathic pain is pain that is caused by a damaged or abnormally functioning nerve. It is a common condition that can be caused by a variety of factors, including diabetes, cancer, and trauma.

SFXN4 is involved in the regulation of pain signaling, and it is thought to play a key role in the development and maintenance of neuropathic pain. It is involved in the production of the pain signal, and it is also involved in the regulation of the response to pain medications.

In conclusion, SFXN4 is a protein that is involved in the development and maintenance of the myelin sheath in the CNS. It has been identified as a potential drug target for multiple sclerosis and chronic pain, and further research is needed to determine its full role in these conditions.

Protein Name: Sideroflexin 4

Functions: Mitochondrial amino-acid transporter (By similarity). Does not act as a serine transporter: not able to mediate transport of serine into mitochondria (PubMed:30442778)

The "SFXN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SFXN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets